The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
The Natural History of Chronic Allograft Nephropathy
Open accessAbstract
BACKGROUND: With improved immunosuppression and early allograft survival, chronic allograft nephropathy has become the dominant cause of kidney-transplant failure. METHODS: We evaluated the natural history of chronic allograft nephropathy in a prospective study of 120 recipients with type 1 diabetes, all but 1 of whom had received kidney-pancreas transplants. We obtained 961 kidney-transplant-biopsy specimens taken regularly from the time of transplantation to 10 years thereafter. RESULTS: Two distinctive phases of injury were evident as chronic allograft nephropathy evolved. An initial phase of early tubulointerstitial damage from ischemic injury (P<0.05), prior severe rejection (P<0.01), and subclinical rejection (P<0.01) predicted mild disease by one year, which was present in 94.2 percent of patients. Early subclinical rejection was common (affecting 45.7 percent of biopsy specimens at three months), and the risk was increased by the occurrence of a prior episode of severe rejection and reduced by tacrolimus and mycophenolate therapy (both P<0.05) and gradually abated after one year. Both subclinical rejection and chronic rejection were associated with increased tubulointerstitial damage (P<0.01). Beyond one year, a later phase of chronic allograft nephropathy was characterized by microvascular and glomerular injury. Chronic rejection (defined as persistent subclinical rejection for two years or longer) was uncommon (5.8 percent). Progressive high-grade arteriolar hyalinosis with luminal narrowing, increasing glomerulosclerosis, and additional tubulointerstitial damage was accompanied by the use of calcineurin inhibitors. Nephrotoxicity, implicated in late ongoing injury, was almost universal at 10 years, even in grafts with excellent early histologic findings. By 10 years, severe chronic allograft nephropathy was present in 58.4 percent of patients, with sclerosis in 37.3 percent of glomeruli. Tubulointerstitial and glomerular damage, once established, was irreversible, resulting in declining renal function and graft failure. CONCLUSIONS: Chronic allograft nephropathy represents cumulative and incremental damage to nephrons from time-dependent immunologic and nonimmunologic causes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033
Solez, K., Axelsen, R. A., Benediktsson, H., Burdick, J. F., Cohen, A. H., Colvin, R. B., Croker, B. P., Droz, D., Dunnill, M. S., Halloran, P. F., et al. (1993) · Kidney International · doi:10.1038/ki.1993.259 · Cited by 1,424
Tolerogenic immunosuppression for organ transplantation
Starzl, T. E., Murase, N., Abu-Elmagd, K., Gray, E. A., Shapiro, R., Eghtesad, B., Corry, R. J., Jordan, M. L., Fontes, P., Gayowski, T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13175-3 · Cited by 499
THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG-TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2
MATAS, A. J., GILLINGHAM, K. J., PAYNE, W. D., & NAJARIAN, J. S. (1994) · Transplantation · doi:10.1097/00007890-199403270-00015 · Cited by 435
Solez, K., Vincenti, F., & Filo, R. S. (1998) · Transplantation · doi:10.1097/00007890-199812270-00029 · Cited by 366
Nickerson, P., Jeffery, J., Gough, J., McKenna, R., Grimm, P., Cheang, M., & Rush, D. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v93482 · Cited by 163
Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients
Bertani, T., Ferrazzi, P., Schieppati, A., Ruggenenti, P. L., Gamba, A., Parenzan, L., Mecca, G., Perico, N., Imberti, O., Remuzzi, A., et al. (1991) · Kidney International · doi:10.1038/ki.1991.206 · Cited by 113
Cyclosporin and renal graft histology.
d'Ardenne, A. J., Dunnill, M. S., Thompson, J. F., et al. (1986) · Journal of Clinical Pathology · doi:10.1136/jcp.39.2.145 · Cited by 61
Glucose homeostasis standards for pancreas transplantation
Nankivell, B. J., Chapman, J. R., Bovington, K. J., et al. (1998) · Clinical Transplantation · doi:10.1111/j.1399-0012.1998.tb00994.x · Cited by 8
Self-citation
Cited by
Sellarés, J., de Freitas, D. G., Mengel, M., Reeve, J., Einecke, G., Sis, B., Hidalgo, L. G., Famulski, K., Matas, A., & Halloran, P. F. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03840.x · Cited by 1,590
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Vincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Costimulation Blockade with Belatacept in Renal Transplantation
Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050085 · Cited by 861
Metadata
- Authors
- Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Allen, R. D. M., & Chapman, J. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-11
- Volume
- 349
- Issue
- 24
- Pages
- 2326-2333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2098974363
- Cited by
- 1,949
- References
- 9
- FWCI
- 45.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.